| Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial BA Wilky, MM Trucco, TK Subhawong, V Florou, W Park, D Kwon, ... The lancet oncology 20 (6), 837-848, 2019 | 306 | 2019 |
| Immune checkpoint inhibitors: The linchpins of modern immunotherapy BA Wilky Immunological reviews 290 (1), 6-23, 2019 | 180 | 2019 |
| Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution V Florou, AE Rosenberg, E Wieder, KV Komanduri, D Kolonias, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 158 | 2019 |
| Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in human chondrosarcoma … L Li, AC Paz, BA Wilky, B Johnson, K Galoian, A Rosenberg, G Hu, ... PloS one 10 (9), e0133813, 2015 | 122 | 2015 |
| Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma I Ramachandran, DE Lowther, R Dryer-Minnerly, R Wang, S Fayngerts, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 115 | 2019 |
| Ultra‐rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities S Stacchiotti, AM Frezza, JY Blay, EH Baldini, S Bonvalot, JVMG Bovée, ... Cancer 127 (16), 2934-2942, 2021 | 106 | 2021 |
| Current and future directions for angiosarcoma therapy V Florou, BA Wilky Current treatment options in oncology 19, 1-13, 2018 | 101 | 2018 |
| Nirogacestat, a γ-secretase inhibitor for desmoid tumors M Gounder, R Ratan, T Alcindor, P Schöffski, WT Van Der Graaf, BA Wilky, ... New England Journal of Medicine 388 (10), 898-912, 2023 | 75 | 2023 |
| Extrathoracic location and “borderline” histology are associated with recurrence of solitary fibrous tumors after surgical resection BA Wilky, EA Montgomery, AA Guzzetta, N Ahuja, CF Meyer Annals of surgical oncology 20, 4080-4089, 2013 | 73 | 2013 |
| Desmoid fibromatosis: MRI features of response to systemic therapy PJ Sheth, S Del Moral, BA Wilky, JC Trent, J Cohen, AE Rosenberg, ... Skeletal radiology 45, 1365-1373, 2016 | 57 | 2016 |
| LGR5 is expressed by Ewing sarcoma and potentiates Wnt/β-catenin signaling CA Scannell, EA Pedersen, JT Mosher, MA Krook, LA Nicholls, BA Wilky, ... Frontiers in oncology 3, 81, 2013 | 55 | 2013 |
| Current status of immunotherapy for gastrointestinal stromal tumor Y Tan, JC Trent, BA Wilky, DA Kerr, AE Rosenberg Cancer gene therapy 24 (3), 130-133, 2017 | 54 | 2017 |
| RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma BA Wilky, C Kim, G McCarty, EA Montgomery, K Kammers, LR DeVine, ... Oncogene 35 (20), 2574-2583, 2016 | 54 | 2016 |
| A dose‐finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma KA Thornton, AR Chen, MM Trucco, P Shah, BA Wilky, N Gul, ... International journal of cancer 133 (4), 997-1005, 2013 | 50 | 2013 |
| Pericytoma With t (7; 12) and ACTB-GLI1 Fusion: Reevaluation of an Unusual Entity and its Relationship to the Spectrum of: GLI1: Fusion–related Neoplasms DA Kerr, A Pinto, TK Subhawong, BA Wilky, MP Schlumbrecht, ... The American journal of surgical pathology 43 (12), 1682-1692, 2019 | 46 | 2019 |
| Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy NS Ezuddin, J Pretell-Mazzini, RL Yechieli, DA Kerr, BA Wilky, ... Skeletal radiology 47, 1595-1606, 2018 | 45 | 2018 |
| Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma K Kikuchi, S Hettmer, MI Aslam, JE Michalek, W Laub, BA Wilky, DM Loeb, ... PLoS genetics 10 (1), e1004107, 2014 | 45 | 2014 |
| A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours BA Wilky, MA Rudek, S Ahmed, DA Laheru, D Cosgrove, RC Donehower, ... British journal of cancer 112 (1), 24-31, 2015 | 44 | 2015 |
| LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer A Bullock, J Grossman, M Fakih, H Lenz, M Gordon, K Margolin, B Wilky, ... Annals of Oncology 33, S376, 2022 | 38 | 2022 |
| A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas MM Trucco, CF Meyer, KA Thornton, P Shah, AR Chen, BA Wilky, ... Clinical Sarcoma Research 8, 1-9, 2018 | 33 | 2018 |
